VIOV Vanguard S&P Small-Cap 600 Value ETF
- 89.821
- -0.759-0.84%
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
P/E Ratio Insights for Organon
Organon Reports Positive Phase 3 Results on Roche Perjuta Biosimilar
Vanguard S&P Small-Cap 600 Value ETF To Go Ex-Dividend On September 27th, 2024 With 0.5071 USD Dividend Per Share
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Organon Analyst Ratings
Russell Companies With the Lowest Tax Rates Expected to Generate $1B in 2025 – GS
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Should Vanguard S&P Small-Cap 600 Value ETF (VIOV) Be on Your Investing Radar?
Morgan Stanley Maintains Equal-Weight on Jackson Finl, Raises Price Target to $89
How Is The Market Feeling About Jackson Finl?
Decoding 6 Analyst Evaluations For Jackson Finl
Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks
Jackson Financial Declares $0.70 Dividend
Organon & Co Snaps Six Days of Losses
Here Is the Next Potential Market Catalyst
Jackson Financial Q2 2024 Earnings Preview
Organon Extends Selloff After Q2 Results